tbuckley/cabot-search huggingface dataset:
NeoPhectin™, a novel cationic cardiolipin liposomes for safe and enhanced transfection of cells
Authors: Pei-Yu Chien, Jinkang Wang, Saifuddin Sheikh, Moghis U. Ahmad, Allen Zhang, Imran Ahmad
Journal: Cancer Research (2004)

4605   Advanced solid tumors, such as melanoma and renal cell cancer, respond to systemic interleukin-2 (IL-2) and/or interferon-γ (IFN-γ), however, both are associated with significant toxicities when administered systemically. Direct injection of a gene transfer agent carrying the coding sequence for IL-2 or IFN-γ should result in local production of high doses of IL-2 or IFN-γ associated local immune stimulation but with lower systemic toxicities. The TG1024 and TG1042 products are non-replicating (E1 and E3 region deleted) recombinant adenoviruses containing human IL-2 or IFN-γ cDNA inserts, respectively. Various pre-clinical studies performed over the past 20 years have suggested a synergistic interaction between cytokines (IFN-α, IFN-γ or IL-2) and certain chemotherapy drugs. It is consequently highly attractive to test this concept of chemo-immunotherapy with the vectors Ad-IL-2 and Ad-IFN-γ with the aim of decreased toxicity and improved efficacy when compared to the use of the corresponding recombinant cytokine, particularly for advanced metastatic cancer. In the murine colon carcinoma CT26 model, the combination of systemic cisplatin administrations with intra-tumoral Ad-IL-2 injections resulted in increased overall survival and frequency of tumor eradication as compared to each treatment modality alone. The combination was also superior in its capacity to eradicate distant, un-treated tumors in mice bearing tumors in each flank. Long term survival was associated with a detectable specific, cellular immune response against CT26 cells as assessed by an ELISPOT assay. There was no evidence that cisplatin curtails the intensity of the cellular immune response against CT26 tumor cells as compared to that obtained with Ad-IL-2 alone. Interestingly,  in vitro  treatment of CT26 cells with cisplatin increased the expression of Fas, FasL, CD80 and CD54. As another example of chemo-immunotherapy, survival of B6D2 mice bearing established B16F0 melanoma tumors was significantly enhanced by the combination of systemic 5-fluorouracil/leucovorin administration together with intra-tumoral Ad-IFN-γ injections when compared to that obtained with Ad-IFN-γ alone. Upregulation of Fas was observed  in vitro  in B16F0 tumor cells in the presence of 5-FU or IFN-γ, suggesting a potential role of the Fas/FasL pathway contributing to the  in vivo  observed effects. Altogether, these pre-clinical data support the idea to test these combinations of chemo-immunotherapy in metastatic cancer patients.
Results of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC)
Authors: D.B. Daniel, C.M. Rudin, L. Hart, D.R. Spigel, M.J. Edelman, J. Goldschmidt, R. Bordoni, B. Glisson, T.F. Burns, A. Dowlati, G. Dy, T.J. Beck, R. Jotte, S.V. Liu, A. Kapoun, L. Faoro, A.C. Chiang
Journal: Annals of Oncology (2017)
Updated results of the SCOT study: An international phase III randomised (1:1) non-inferiority trial comparing 3 versus 6 months of oxaliplatin based adjuvant chemotherapy for colorectal cancer
Authors: T. Iveson, R. Kerr, M. Saunders, N. Hollander, J. Tabernero, A. Haydon, B. Glimelius, A. Harkin, C. Scudder, K. Boyd, A. Waterston, L. Medley, C. Wilson, R. Ellis, S. Essapen, A. Dhadda, M. Harrison, S. Falk, S. Abdel-Raouf, J. Paul
Journal: Annals of Oncology (2017)
A randomized, double-blind study of PF-05280014 (a potential trastuzumab biosimilar) vs trastuzumab, both in combination with paclitaxel, as first-line treatment for HER2-positive metastatic breast cancer
Authors: M. Pegram, E. Tan-Chiu, A. Freyman, A. Vana, F. Hilton, C. Zacharchuk, R. Ewesuedo
Journal: Annals of Oncology (2017)
Telangiectasias on the Lower Extremity
Authors: Jennifer Nicole Harb, Stephanie J. Carstens, Kiran Motaparthi
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Neoadjuvant chemotherapy of docetaxel and carboplatin in patients with stage Ib2 to IIb nonsquamous cervix cancer of the uterus.
Authors: Shoji Nagao, Muneaki Shimada, Keiichi Fujiwara, Nobuhiro Takeshima, Ken Takizawa, Tadahiro Shoji, Toru Sugiyama, Satoshi Yamaguchi, Ryuichiro Nishimura, Junzo Kigawa
Journal: Journal of Clinical Oncology (2012)

5103 Background: Non-squamous carcinoma of the uterine cervix has a resistance to radiation therapy and chemotherapy, and this is associated with worse prognosis compared with squamous carcinoma. This is a phase II study to assess an efficacy and safety of neoadjuvant chemotherapy of docetaxel and carboplatin (DC therapy) in patients with stage Ib2 to II non-squamous cervix cancer of the uterus. Methods: Patients with histologically confirmed, stage Ib2-II non-squamous uterine cervix cancer were received DC therapy prior to type III radical hysterectomy. IV doceaxel was administered at 60 mg/m 2 followed by IV carboplatin administration based on AUC=6. The treatment was repeated every 21 days for a total of 1 to 3 cycles. Surgery was performed as soon as sufficient response was obtained. Results: Fifty-three women with non-squamous cervical carcinoma (FIGO stage Ib2,15; IIa, 7; IIb, 31) received DC therapy. Median age and tumor size were 49 years old (range: 27-71) and 52mm (range: 10-92), respectively. Fourty of 47 patients (74%) received 2 cycles of chemotherapy. Clinical response occurred in 69.8% of patients (complete response, 5; partial response, 32; stable disease, 15; disease progression, 1), and 96% (52/54) of patients completed the surgery. Incidences of grade 3/4 hematological toxicities were 98% (53/54) for neutrocytopenia, 4% (2/54) for thrombocytopenia, and 9% (5/54) for anemia. Febrile neutropenia was observed in three patients. Observed grade 3/4 non-hematological toxicities included were 5 for nausea, 2 for vomiting, 3 for constipation, 4 for allergic reaction. Median follow-up duration was 860 days with a range of 147- 1635 days. The 2-years progression-free survival rate and 2-years overall survival rate were 63% and 79% in stage IB2, 71% and 86% in stage IIA2, and 67% and 86% in stage IIB, respectively.Twenty patients recurred and twelve patients died. Conclusions: Neoadjuvant chemotherapy using DC therapy was well tolerated and had good response. It seems to be benefical in patients with satge Ib2 to II nonsquamous cervical cancer.
Effect of Different Iron Preparations for Young Children With Iron-Deficiency Anemia—Reply
Authors: Jacquelyn M. Powers, George R. Buchanan, Timothy L. McCavit
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A pilot study to evaluate the feasibility, usability, and perceived satisfaction with eCO (eCediranib-Olaparib), a mobile application for side effect monitoring and reporting, in women with recurrent ovarian cancer
Authors: J. Liu, C. Whalen, S. Morrissey, E. Komatsu, J-M. Lee, N. Houston, R.M. Wenham, D.M. O'Malley, E. Strock, R. Phillips, K. Mari, S.P. Ivy, B. Killam
Journal: Annals of Oncology (2017)
Use of changes in blood flow PET measurements to predict post-therapy lymph node status among locally advanced breast cancer patients
Authors: D. A. Mankoff, L. Dunnwald, J. Gralow, G. Ellis, H. Linden, J. Specht, R. Doot, W. Barlow, E. Schubert, R. Livingston
Journal: Journal of Clinical Oncology (2007)

575 Background: Response to neoadjuvant therapy in the primary tumor and nodal metastasis predicts benefit to patients as shown in several large clinical trials. We have previously shown that changes in tumor blood flow (BF) measured by [15O]-water PET predict pathologic primary tumor response. We now test whether primary tumor blood flow changes also predict axillary nodal metastases response and post-therapy lymph node status among women with locally advanced breast cancer (LABC) receiving neoadjuvant chemotherapy. Methds: Fifty-five women with a primary diagnosis of LABC underwent dynamic [15O]-water PET scans prior to and at midpoint of neoadjuvant chemotherapy. We evaluated associations between tumor BF changes and pathologic primary tumor response: categorized as complete (CR), partial (PR) or no response (NR). We also assessed the relationship between primary tumor BF changes and post-therapy axillary lymph node status, categorizing the high risk (HR) group as 4+ nodes with extracapsular extension (ECE, n=12) versus the lower risk (LR) group with either fewer than 4+ nodes or without ECE (n=43). Results: The median changes in BF versus tumor response were: CR = -77%, PR = -40%, and, NR = +20% (P = &lt;0.001). For axillary node response, the median BF change among HR patients was +20% versus - 49% among LR patients (P = 0.004). Eight of 17 patients with an increase in tumor blood flow were HR whereas 4/38 patients with decreased tumor blood flow were HR (P = 0.002). Conclusions: Change in primary tumor blood flow over the course of neoadjuvant chemotherapy predicts pathologic response to treatment with a substantial decrease observed among CRs. An increase in primary tumor BF with treatment portends significant residual primary tumor and a nearly 50% chance of very high-risk nodal disease post-therapy. No significant financial relationships to disclose.
GW28-e0577 Trimethylamine-N-oxide induces the osteogenic responses of human aortic valve interstitisl cells through the endoplasmic reticulum-mitochondrial stress pathways
Authors: Jiaying Li, Qingchun Zeng, Xi Yang, Tianyu Xu, Dongqi An, Qiong Zhan, Xingfu Huang, Yan Tu, Wenyan Lai, Dingli Xu
Journal: Journal of the American College of Cardiology (2017)
Abstract 13728: Changes in Myocardial Function Following 8 to 12-hour Rebreathing Cold Water Dives
Authors: Romain Chopard, Loic Barrot, Francois Belon, Francois-Xavier Brocq, Jean-Christophe Blanchard, Jean-Eric Blatteau, Christophe Peny, Jacques Regnard, Olivier Castagna
Journal: Circulation (2014)

Aim: This study assessed hemodynamic changes and myocardial function after prolonged dynamic cold water immersions with hyperbaric hyperoxic exposure. Methods: Trained military divers were studied during 8-hour (6 subjects) and 12-hour (6 subjects) dives in a hyperbaric chamber (1.7 and 3 bar) in 18°C water. Subjects were breathing hyperoxic gas (100% oxygen or up to 1.7 bar PO2) and performed bouts of physical exercise. Conventional and speckle tracking transthoracic echocardiography (TTE) were performed before, immediately after, and 15 hours after dives. Results: We observed a decrease in left and right ventricular preloads, and lowered stroke volume immediately after dives. These parameters remained below baseline values 15h after dive termination. These changes were not significantly different between 8h and 12h dives. Speckle tracking analysis showed altered function of the left and right ventricles reflected by a transient decrease in ventricular parameters as measured by echography in the hour immediately after the end of immersion (table). Conclusion: Hemodynamic changes and transient alterations in strain and strain rate myocardial parameters were assessed immediately after 8 to 12 h dives. Immersion-linked changes in blood volume were likely involved in lowering cardiac preload and stroke volume. Altered ventricular strain and strain rates could be the result of lowered blood volume, hyperoxic breathing and increased cardiac pre- and after-load.
Overall survival (OS) for first-line crizotinib versus chemotherapy in ALK+ lung cancer: Updated results from PROFILE 1014
Authors: T.S.K. Mok, D-W. Kim, Y-L. Wu, K. Nakagawa, T. Mekhail, E. Felip, F. Cappuzzo, J. Paolini, T. Usari, K. Wilner, F. Blackhall, B.J. Solomon
Journal: Annals of Oncology (2017)
Echocardiographic estimation of left ventricular and pulmonary pressures in patients with heart failure and preserved ejection fraction: a study utilizing simultaneous echocardiography and invasive measurements
Authors: Yoran M. Hummel, Licette C.Y. Liu, Carolyn S.P. Lam, Daniel F. Fonseca‐Munoz, Kevin Damman, Michiel Rienstra, Peter van der Meer, Stephan Rosenkranz, Dirk J. van Veldhuisen, Adriaan A. Voors, Elke S. Hoendermis
Journal: European Journal of Heart Failure (2017)
Immune function and response to neoadjuvant chemotherapy in hormone receptor positive, HER2-negative breast cancer
Authors: A. Matikas, J. Lövrot, A. Ramberg, M. Eriksson, T. Lindsten, T. Lekberg, I. Hedenfalk, N. Loman, J. Bergh, A. Erlandsson, T. Hatschek, T. Foukakis
Journal: Annals of Oncology (2017)
Effect on quality of life (QOL) of adding cisplatin to single-agent first-line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC): A joint analysis of the multicentre, randomized, phase 3 MILES-3 and MILES-4 studies
Authors: M.C. Piccirillo, A. Morabito, P. Maione, A. Luciani, L. Cavanna, L. Bonanno, E. Piazza, S. Leo, S. Cinieri, F. Morgillo, M.A. Burgio, D. Bilancia, F. Rosetti, A. Montanino, A. Manzo, L. Arenare, S. Signoriello, C. Gallo, F. Perrone, C. Gridelli
Journal: Annals of Oncology (2017)
Prevalence of malnutrition in PS 0-1 cancer patients: Results of the NutriCancer2 one-day national survey in 2,197 cancer patients.
Authors: Jean-Philippe Durand, Xavier Hebuterne, Bruno Raynard, Jean Lacau Saint Guily, Francois Goldwasser
Journal: Journal of Clinical Oncology (2015)

1587 Background: The performance status (PS) measured by the ECOG scale, and malnutrition are both prognostic and risk factors for treatment-related toxicities in cancer patients (pts). In the medical literature, pts characteristics are usually limited to PS without description of the nutritional status. There is a serious issue concerning the under-estimation of the risk prior to anticancer treatments initiation. The prevalence of malnutrition in “fit” PS 0-1 pts remains unknown. Methods: We conducted a prospective one-day prevalence survey, NUTRICANCER 2, in 283 wards of private or public hospitals in France in 2012. Height, present and usual body weight were systematically assessed in out-pts and in-pts. Malnutrition was defined as a BMI < 18.5 or < 21 in pts older than 75 years, or a loss of body weight > 10% since the diagnosis of malignancy. Results: A total of2197 patients (1,132 men and 1,046 women, 19 not evaluable) were included. PS alteration was significantly more frequent in malnourished patients. Indeed, 58.9% of pts with malnutrition had a PS > 2 versus 31% of pts without malnutrition. Malnutrition was found in 48.1% (276/574), 66.7% (166/249), and 69.8% (44/63) of the pts with a PS ranging from 2 to 4, respectively (chi2 = 223.95; p < 0.001). In pts assumed as fit for chemotherapy, the prevalence of malnutrition was 17.3% (76/440) in PS0 and 33.2% (262/790) in PS1 pts. Almost one third of the patients with apparent good general status were already malnourished and therefore at high risk of severe acute toxicity. Conclusions: This national prevalence survey indicates that Performance Status is not sensitive enough for risk assessment in oncology, requiring a systematic nutritional status assessment prior to anticancer treatments initiation.
Predictive factors for poor progression-free survival in patients with non-small-cell lung cancer treated with nivolumab
Authors: Y. Taniguchi, A. Tamiya, S-I. Isa, K. Nakahama, K. Okishio, T. Shiroyama, H. Suzuki, T. Inoue, M. Tamiya, K. Nishino, T. Kumagai, T. Hirashima, F. Imamura, S. Atagi
Journal: Annals of Oncology (2017)
Baseline neutrophil-to-lymphocyte ratio (NLR) and early toxicity as prognostic factors in advanced hepatocellular carcinoma patients treated with sorafenib.
Authors: Gema Bruixola, Oscar Mauricio Niño, Robert Diaz-Beveridge, Encarnacion Reche, Carmen Salvador, Corina Escoin, Dilara Akhoundova, Angel Segura, Alejandra Gimenez, Jorge Aparicio
Journal: Journal of Clinical Oncology (2015)

e15159 Background: Sorafenib improves overall survival (OS) in patients (pts) with advanced hepatocellular carcinoma (HCC). An elevated baseline NLR has been reported as a possible poor prognostic factor in several tumors, including HCC. Early-onset toxicity with sorafenib has also been linked with a better prognosis. Methods: Retrospective review of sorafenib-treated pts (2008-2014). Baseline NLR, overall toxicity, early toxicity rates (onset in 1st 30 days), progression-free survival (PFS) and OS were assessed. Univariate and multivariate analysis of prognostic factors for OS was performed. Results: 145 pts found. Baseline characteristics in Table 1. Overall G3-4 toxicities: fatigue (19.3%), hand-foot syndrome (HFS) (8.3%) and diarrhea (7.6%). Early toxicities (all grades): diarrhea and HFS in 42.2% and 20.8%. With a median follow-up of 43 months (mts), median PFS and OS was 4.15 (CI95% 2,5-5,8) and 6.7 mts (CI95% 4,5-8,8), respectively, with a 1-year OS of 33%. Univariate analysis: Performance status (PS) 0-1, Child-Pugh (C-P) A score, no portal vein thrombosis, prior local therapies, G3-4 diarrhea or HFS, early-onset diarrhea and a low NLR score (<4) were all significant prognostic factors for a better OS. In the multivariate study, only PS, C-P score, early-onset diarrhea and a low NLR score retained their significant prognostic value. Conclusions: A higher percentage of pts with impaired liver function might justify the poorer survival outcomes seen compared to published phase III data. Early-onset digestive toxicity and a low baseline NLR score should be evaluated prospectively as prognostic features, alongside well-established clinical characteristics such as PS and C-P score in order to better identify those pts who could benefit preferentially with the use of sorafenib. Characteristics (n 145) n (%) Median age, yrs (range) 62 (26-82) PS 0-1 2 135 (93.1) 10 (6,9) Male sex 109 (75,2) CirrhosisNon cirrhosis 118 (81,4) 27 (18,5) C-P score A B 106 (73.1) 39 (26.9) Barcelona Clinic Liver Cancer staging (BCLC) B C 25 (17.2) 120 (82.8) Portal vein thrombosis 52 (35,9) Distant metastasis 78 (54) Prior local therapies 86 (61) NLR score <4 95 (69.9)
GW28-e0774 Difference in Fluid overload in symptomatic and asymptomatic patients with heart failure
Authors: Thach Nguyen, Luong Thanh Phuoc, Tran Ngoc Minh Chau, Khanh Duong, Nguyen Khanh Duy, Nguyen Phuc Hieu
Journal: Journal of the American College of Cardiology (2017)
BRIM8: a randomized, double-blind, placebo-controlled study of adjuvant vemurafenib in patients (pts) with completely resected, BRAFV600+ melanoma at high risk for recurrence
Authors: K. Lewis, M. Maio, L. Demidov, M. Mandala, P.A. Ascierto, C. Herbert, A. Mackiewicz, P. Rutkowski, A. Guminski, G. Goodman, B. Simmons, C. Ye, Y. Yan, D. Schadendorf
Journal: Annals of Oncology (2017)
Acción Concertada Europea sobre la Borreliosis de Lyme (EUCALB)
Authors: S O’Connell
Journal: Eurosurveillance (1996)

La incertidumbre sobre el alcance del problema que representa la  de Lyme, el riesgo de secuelas graves y las poco satisfactorias tecnicas de laboratorio utilizadas para su investigacion, han dado lugar a la colaboracion de investigadores de 12 paises de la Union Europea (UE) y de dos naciones del bloque oriental. La European Union Concerted Action on Lyme Borreliosis (EUCALB), fundada por la UE bajo su programa Biomed 1, dirigida por el Dr Jeremy Gray del University College de Dublin, coordina la investigacion sobre la ecologia, biologia molecular, taxonomia y distribucion geografica dentro de Europa de Borrelia burgdorferi, asi como las caracteristicas clinicas y epidemiologicas de la  de Lyme en Europa, los factores de riesgo de infeccion para el hombre y las medidas de prevencion, incluido los programas de formacion destinados a zonas endemicas.
Reply to ‘Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials’: reply from the authors
Authors: W. Rungapiromnan, Z.Z.N. Yiu, R.B. Warren, C.E.M. Griffiths, D.M. Ashcroft
Journal: British Journal of Dermatology (2017)

We would like to thank Drs Amin, No and Wu for their interest in our recent publication.2 We are pleased to note, in particular, how much we agree on one fundamental point - there is a need for future well-designed studies that involve larger numbers of patients and longer durations of treatment exposure in order to better assess the impact of biologic therapies on the risk of major adverse cardiovascular events (MACEs) in patients with psoriasis.

This article is protected by copyright. All rights reserved.
Authors' reply: Benefit and risks of trivalent 2010 seasonal influenza vaccine in Australian children
Authors: H Kelly, D Carcione, G Dowse, P Effler
Journal: Eurosurveillance (2010)

Preview this article: Authors' reply: Benefit and risks of trivalent 2010 seasonal influenza vaccine in Australian children, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/15/40/art19681-en-1.gif
Prognostic impact of the neutrophil-to-lymphocyte ratio (NLR) on overall survival in patients treated with chemoradiotherapy for head and neck cancer
Authors: S. Makhloufi, G. Lefebvre, I. Sakji, F. Feutry, T. Leroy, N. Penel, B. Coche, J. Fourquet, F. Ghestem, M. Julieron, D. Chevalier, E. Tresch
Journal: Annals of Oncology (2017)
One-year safety, immunogenicity, and survival results from a phase III study comparing SB3 (a proposed trastuzumab biosimilar) and originator trastuzumab in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment
Authors: X. Pivot, I.M. Bondarenko, Z. Nowecki, M. Dvorkin, E. Trishkina, J.H. Ahn, Y. Vinnyk, S-A. Im, T. Sarosiek, S. Chatterjee, M. Wojtukiewicz, V. Moiseyenko, Y. Shparyk, M. Bello III, V. Semiglazov, L. Younju, J. Lim
Journal: Annals of Oncology (2017)